We present the cases of two elderly patients with intermittent long-term tramadol intake against chronic back pain. Over a period of more than two years they experienced fluctuating confusional states and cognitive deficits, reversible only after discontinuation of tramadol. According to the DSM IV-criteria, an unrecognised recurrent tramadol-induced delirium can be diagnosed in both cases. Although tramadol may represent a well established safe therapy for chronic non-malignant pain in the elderly, these cases demonstrate that it should be applied with caution even in healthy subjects.
References
1
Bailer U, Fischer P, Kufferle B, Stastny J, Kasper S.
Occurrence of mirtazapine-induced delirium in organic brain disorder.
Int Clin Psychopharmacol.
2000;
15
239-243
2
Christensen DB, Benfield WR.
Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients.
J Am Geriatr Soc.
1998;
46
620-625
3
Degner D, Grohmann R, Kropp S, Rüther E, Bender S, Engel RR, Schmidt LG.
Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP.
Pharmacopsychiatry.
2004;
37
((Suppl 1))
39-45
4
Devulder J, De Laat M, Dumoulin K, Renson A, Rolly G.
Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.
Acta Clin Belg.
1996;
51
184-186
5
Elie M, Cole MG, Primeau FJ, Bellavance F.
Delirium risk factors in elderly hospitalized patients.
J Gen Intern Med.
1998;
13
204-212
6
Ersek M, Cherrier MM, Overman SS, Irving GA.
The cognitive effects of opioids.
Pain Manag Nurs.
2004;
5
75-93
7
Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH.
Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.
Arch Intern Med.
2003;
163
2716-2724
8
Grond S, Sablotzki A.
Clinical pharmacology of tramadol.
Clin Pharmacokinet.
2004;
43
879-923
9
Houlihan DJ.
Serotonin syndrome resulting from co-administration of tramadol, venlafaxine, and mirtazapine.
Ann Pharmacother.
2004;
38
411-413
10
Ishikawa E, Yanaka K, Sugimoto K, Ayuzawa S, Nose T.
Reversible dementia in patients with chronic subdural hematomas.
J Neurosurg.
2002;
96
680-683
11
Laurila JV, Pitkala KH, Strandberg TE, Tilvis RS.
The impact of different diagnostic criteria on prevalence rates for delirium.
Dement Geriatr Cogn Disord.
2003;
16
156-162
12
Laurila JV, Pitkala KH, Strandberg TE, Tilvis RS.
Delirium among patients with and without dementia: does the diagnosis according to the DSM-IV differ from the previous classifications?.
Int J Geriatr Psychiatry.
2004;
19
271-277
13
Lee KU, Won WY, Lee HK, Kweon YS, Lee CT, Pae CU, Bahk WM.
Amisulpride versus quetiapine for the treatment of delirium: a randomized, open prospective study.
Int Clin Psychopharmacol.
2005;
20
311-314
14
Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili J, Scheltens P, Vellas B, Touchon J.
Mild Cognitive Impairment in medical practice: critical review of the concept and new diagnostic procedure. Report of the MCI working group of the European Consortium on Alzheimer's disease (EADC).
J Neurol Neurosurg Psychiatry.
2006;
, March 20 [Epub ahead of print]
15
Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH.
The hypoalgesic effect of tramadol in relation to CYP2D6.
Clin Pharmacol Ther.
1996;
60
636-644
16
Radbruch L, Grond S, Lehmann KA.
A risk-benefit assessment of tramadol in the management of pain.
Drug Saf.
1996;
15
8-29
17
Soyka M, Backmund M, Hasemann S.
Tramadol use and dependence in chronic noncancer pain patients.
Pharmacopsychiatry.
2004;
37
191-192
18
Spiller HA, Gorman SE, Villalobos D, Benson BE, Ruskosky DR, Stancavage MM, Anderson DL.
Prospective multicenter evaluation of tramadol exposure.
J Toxicol Clin Toxicol.
1997;
35
361-364
19
Weber JB, Coverdale JH, Kunik ME.
Delirium: current trends in prevention and treatment.
Intern Med J.
2004;
34
115-121
Correspondence
Gabriella Künig
Department of Psychiatry·University of Zurich·Division of Psychogeriatric Medicine
Lenggstrasse 31·Postfach 1931·8029 Zürich·Switzerland
Phone: +41/44/384 27 82
Fax: +41/44/384 26 87
Email: gabriella.kuenig@puk.zh.ch